Cantargia AB (publ) (FRA:7V3)

Market Cap	95.69M
Revenue (ttm)	27.92M
Net Income (ttm)	12.66M
Shares Out	n/a
EPS (ttm)	0.05
PE Ratio	7.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	310
Open	0.3435
Previous Close	0.2995
Day's Range	0.3435 - 0.3435
52-Week Range	0.0635 - 0.3545
Beta	n/a
RSI	56.09
Earnings Date	Nov 19, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7V3

Financial Performance

Financial numbers in SEK